Authors' response to comment on “Omega-3 polyunsaturated fatty acids in critically ill patients with acute respiratory distress syndrome: a systematic review and meta-analysis”

• Published in: Nutrition (Burbank, Los Angeles County, Calif.) Los Angeles County, Calif.), 2021-10, Vol.90, p.111432-111432, Article 111432
• Main Authors: Manzanares, William, Hardy, Gil, Langlois, Pascal L
• Format: Article
• Language: English
• Subjects: Bias; Clinical trials; Confidence intervals; Fatty acids; Immunomodulation; Meta-analysis; Nutrition; Polyunsaturated fatty acids; Respiratory distress syndrome; Sensitivity analysis; Subgroups; Systematic review
• ISSN: 0899-9007; 1873-1244
• DOI: 10.1016/j.nut.2021.111432

[...]we did conduct subgroup and sensitivity analyses on all outcomes, to substantiate the positive findings [2]. Because the majority of recent FO publications have also included IED cocktails, we would argue that excluding the IED trials with other immunomodulatory agents would lead to a massive elimination of interesting RCTs using ω-3 PUFAs. After several failed attempts to contact the authors, we finally decided to exclude the article from our analysis. [...]we consider that all the eligible published clinical trials that met our inclusion criteria were included in our systematic review [2]. According to our results, FO administration was associated with a significant improvement in early PaO2-to-FiO2 ratio (weighted mean difference (WMD) = 49.33; 95% confidence interval [CI], 20.88–77.78; P = 0.0007; I2 = 69%), which persisted at days 7 to 8 (WMD = 27.87; 95% CI, 0.75–54.99; P = 0.04; I2 = 57%) [2].